2010/06/23

Lavomax

Composition, structure and packing

Coated tablets from yellow to orange, round, on the cross section shows two layer tablet core orange. 1 tab. Tilorone 125 mg.

Excipients: magnesium gidroksikarbonata hydroxide, povidone (polyvinylpyrrolidone low molecular medicine), calcium stearate, colloidal silicon dioxide (Aerosil), beeswax, vaseline oil, sucrose, talc, tropeolin Oh, titanium dioxide, polyethylene glycol high molecular 6000 (pending receipt of tablets weighing 0.39 g ).

Clinico-pharmacological group: Antiviral and immunomodulatory drugs. Inductor synthesis of interferon

Pharmacological action

Antivirus and immunomodulatory drugs. Lavomax stimulates the body's α-, β-, γ-interferon. In response to the introduction Lavomax interferon is produced mainly by cells of the intestinal epithelium, hepatocytes, T-lymphocytes and neutrophils.

After taking the drug inside a maximum production of interferon is defined in the sequence gut-liver-blood through the 4-24 hours Lavomax has immunomodulating and antiviral action. Stimulates bone marrow stem cells in a dose-dependent increases antibody production, reduces the degree of immunosuppression, restores ratio T-helpery/T-supressory.

It is effective against various viral infections, including against influenza and other acute respiratory viral infections, hepatitis viruses and herpes viruses. The mechanism of antiviral activity is associated with inhibition of translation of virus-specific proteins in infected cells, as a result of this is suppressed virus reproduction.

Pharmacokinetics

Absorption

After taking the drug inside Tilorone rapidly absorbed from the gastrointestinal tract. Bioavailability is 60%.

Distribution

Linking to plasma proteins - about 80%.

Metabolism and excretion

Tilorone not Biotransformation and not cumulative in the body. We derive a practically unchanged in the feces (70%) and urine (about 9%). T1 / 2 was 48 h.

Statement

The drug used in adults.
influenza and SARS (prophylaxis and treatment);
viral hepatitis A, B and C;
herpes infection;
cytomegalovirus infection;
in complex therapy of infectious-allergic and viral encephalomyelitis (multiple sclerosis, leykoentsefality, uveoentsefality);
in the complex therapy of urogenital and respiratory chlamydia.

Dosage regimen

For the prevention of influenza and SARS Lavomax appoint a dose of 125 mg 1 time per week for 6 weeks.

For treatment of influenza and other acute respiratory viral infection in the first 2 days of illness appoint 125 mg / day, then 125 mg every 48 hours Coursework dose - 750 mg (6 pills)..

For the nonspecific prophylaxis of viral hepatitis A drug prescribed in a dose of 125 mg per week for 6 weeks.

In the treatment of viral hepatitis A dose on the first day is 125 mg 2 times / day, then - by 125 mg every 48 h. The course of treatment - 1.25 g (10 tablets)..

In the treatment of acute hepatitis B in the first and second day - 125 mg / day, then - 125 mg every 48 h. The course of treatment - 2 g (16 tab.).

With prolonged duration of hepatitis B in the first day - 125 mg 2 times / day, then - 125 mg every 48 hours course of treatment - 2.5 g (20 tab.).

In chronic hepatitis B in the initial phase of treatment (2.5 g - 20 tab). In the first 2 days - 250 mg, then 125 mg every 48 h. In the continuation phase of treatment (from 1.25 g - 10 Tab. Up to 2.5 g - 20 pi.) - 125 mg per week. Heading dose Lavomax ranging from 3.75 g to 5 g, duration of treatment is 3.5-6 months depending on the results of biochemical, immunological and morphological studies, reflecting the degree of activity of the process.

In acute hepatitis C in the first and second days of treatment prescribed for 125 mg, then - by 125 mg every 48 h. The course of treatment - 2.5 g (20 tab.).

In chronic hepatitis C in the initial phase of treatment (2.5 g - 20 tab.) In the first 2 days - 250 mg / day, then - 125 mg every 48 h. In the continuation phase of treatment (2.5 g - 20 tab.) Appoint 125 mg per week. Heading dose Lavomax - 5 g, duration of treatment is 6 months, depending on the results of biochemical, immunological and morphological studies, reflecting the degree of activity of the process.

For the treatment of herpes, cytomegalovirus infection dose in the first 2 days of 125 mg, then take 125 mg in 48 hours course dosage - 2.5 PM

Urogenital and respiratory chlamydiosis Lavomax in the first two days appoint a dose of 125 mg / day, then - 125 mg every 48 hours Coursework dose - 1.25 g (10 tab.).

The comprehensive treatment of infections neyrovirusnyh dose set individually, the duration of the course - 4 weeks.

Drug is taken orally after meal.

Side effect

On the part of the digestive system: in some cases - symptoms of dyspepsia.

Other: possible intermittent fever, allergic reactions

Contraindications
Pregnancy
Lactation (breastfeeding);
Children under 7 years;
Hypersensitivity to the drug.

Pregnancy and lactation

Lavomax contraindicated during pregnancy and lactation (breastfeeding).

Cautions

Lavomax compatible with antibiotics, and the means of the traditional treatment of viral and bacterial infections.

Overdose

So far, cases of overdosing Lavomax not reported.

Drug Interactions

Clinically significant drug interactions Lavomax with antibiotics and the means of the traditional treatment of viral and bacterial infections have been detected ..

Terms and Conditions of storage

The drug should be stored out of reach of children, dry, dark place at temperatures not above 25 ° C. Shelf life - 2 years.